Vincent M. Figueredo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vincent M. Figueredo has a total of 366 co-authors. Here are the top co-authors by number of shared publications:
- Mahek Shah
Department of Cardiology, Lehigh Valley Hospital Network, Allentown, Pennsylvania
12 shared publications D. Lynn Morris
8 shared publicationsCarlos D. Davila
The CardioVascular Center, Tufts Medical Center, Boston, Massachusetts
7 shared publicationsVikas Bhalla
7 shared publications- Chinualumogu Nwakile
Einstein Institute for Heart and Vascular Health, Einstein Medical Center, Philadelphia, PA, United States
6 shared publications Deepakraj Gajanana
Albert Einstein Medical Center, Philadelphia, PA
6 shared publications
Latest Publications
- Open Access
- 31 May 2020
- Published by Springer Nature in Cureus
- Vol. 12 (5) , e8380
Aspiration Thrombectomy Versus Stent Retriever Thrombectomy Alone for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
This meta-analysis was conducted to assess the safety and efficacy of aspiration thrombectomy versus stent retriever thrombectomy for acute ischemic stroke (AIS). We queried online databases for original studies comparing aspiration thrombectomy with stent retriever thrombectomy in patients with AIS. After article selection, data were extracted on multiple baseline characteristics and prespecified endpoints. Dichotomous data were presented as risk ratios (RRs) and corresponding 95% confidence intervals (CIs); continuous data as mean differences and 95% CIs. The data were pooled using a random-effects model. Subgroup analysis was conducted based on study type, site of occlusion, and age. We shortlisted nine relevant studies (n=1453 patients; n=690 receiving aspiration thrombectomy and n=763 receiving stent retriever thrombectomy). Meta-analysis demonstrated no significant difference between the two groups in the rates of successful recanalization (RR: 0.96 [0.87, 1.06]; p=0.42), excellent functional outcome (RR: 0.90 [0.80, 1.01]; p=0.06), or procedure time (weighted mean difference (WMD): -5.39 minutes [-11.81, 1.04]; p=0.10). However, when removing the study by Nishi et al., sensitivity analysis resulted in a significant reduction in procedure time with aspiration (WMD: -11.01 [-15.54, -6.49]; p65 (RR: 0.89 [0.80, 1.00]; p=0.05). Our updated meta-analysis reveals that both aspiration and stent retriever thrombectomy are comparably effective in the management of AIS. Shorter procedure times may potentially be attained with aspiration thrombectomy, and outcomes with each procedure may be age-dependent.
- 31 May 2020
- Published by Springer Nature in Cureus
- Vol. 12 (5) , e8380
Open AccessAspiration Thrombectomy Versus Stent Retriever Thrombectomy Alone for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
This meta-analysis was conducted to assess the safety and efficacy of aspiration thrombectomy versus stent retriever thrombectomy for acute ischemic stroke (AIS). We queried online databases for original studies comparing aspiration thrombectomy with stent retriever thrombectomy in patients with AIS. After article selection, data were extracted on multiple baseline characteristics and prespecified endpoints. Dichotomous data were presented as risk ratios (RRs) and corresponding 95% confidence intervals (CIs); continuous data as mean differences and 95% CIs. The data were pooled using a random-effects model. Subgroup analysis was conducted based on study type, site of occlusion, and age. We shortlisted nine relevant studies (n=1453 patients; n=690 receiving aspiration thrombectomy and n=763 receiving stent retriever thrombectomy). Meta-analysis demonstrated no significant difference between the two groups in the rates of successful recanalization (RR: 0.96 [0.87, 1.06]; p=0.42), excellent functional outcome (RR: 0.90 [0.80, 1.01]; p=0.06), or procedure time (weighted mean difference (WMD): -5.39 minutes [-11.81, 1.04]; p=0.10). However, when removing the study by Nishi et al., sensitivity analysis resulted in a significant reduction in procedure time with aspiration (WMD: -11.01 [-15.54, -6.49]; p65 (RR: 0.89 [0.80, 1.00]; p=0.05). Our updated meta-analysis reveals that both aspiration and stent retriever thrombectomy are comparably effective in the management of AIS. Shorter procedure times may potentially be attained with aspiration thrombectomy, and outcomes with each procedure may be age-dependent.
- 1 April 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (8) , 1220-1227
Trends in Incidence and Outcomes of Pregnancy-Related Acute Myocardial Infarction (From a Nationwide Inpatient Sample Database)
- 1 April 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (8) , 1220-1227
Trends in Incidence and Outcomes of Pregnancy-Related Acute Myocardial Infarction (From a Nationwide Inpatient Sample Database)
- 1 April 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (4) , 505-509
Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis
- 1 April 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (4) , 505-509
Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis
- 1 January 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (2) , 218-226
Meta-analysis Comparing Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction and Cardiogenic Shock
- 1 January 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 123 (2) , 218-226
Meta-analysis Comparing Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction and Cardiogenic Shock
- Open Access
- 19 November 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (11) , 1423-1429
National trends in hospitalizations and outcomes in patients with alcoholic cardiomyopathy
Background: Numerous studies have shown conflicting results regarding the natural history and outcomes with alcoholic cardiomyopathy (AC).Hypothesis: Determining the trends in hospitalization among patients with AC and associated outcomes will facilitate a better understanding of this disease.Methods: We conducted our analysis on discharge data from the Healthcare Cost and Utilization Project‐Nationwide Inpatient Sample (HCUP‐NIS) from 2002 through 2014. We obtained data from patients aged ≥18 years with diagnosis of “Alcoholic Cardiomyopathy.” Death was defined within the NIS as in‐hospital mortality. By using International Classification of Disease‐9th edition‐Clinical Modification (ICD‐9CM) diagnoses and diagnosis‐related groups different comorbidities were identified.Results: We studied a total of 45 365 admissions among patients with AC. The absolute number of admissions decreased from 2002 to 2014 (3866‐2834 admissions). In‐hospital mortality was variable throughout study duration without a clinically relevant trend (Mean 4.5%, range 3.6%‐5.6%). The patients were mostly male (87%) and Caucasian (50.5%). Commonest age groups involved were 45‐59 years (46.7%) followed by 60‐74 years (29.2%). Trends in associated comorbidities such as smoking, drug abuse, depression, and hypertension increased over the same time period. Among all admissions, almost half were for cardiovascular etiologies (48.9%) and heart failure (≈24%) was the commonest reason for hospital admission.Conclusion: While the overall admissions among patients with AC decreased over time, the proportion of patients with high‐risk characteristics such as smoking, depression, and drug abuse increased. Patients aged 45 and older were largely affected and cardiovascular etiologies predominated among causes for admission.
- 19 November 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (11) , 1423-1429
Open AccessNational trends in hospitalizations and outcomes in patients with alcoholic cardiomyopathy
Background: Numerous studies have shown conflicting results regarding the natural history and outcomes with alcoholic cardiomyopathy (AC).Hypothesis: Determining the trends in hospitalization among patients with AC and associated outcomes will facilitate a better understanding of this disease.Methods: We conducted our analysis on discharge data from the Healthcare Cost and Utilization Project‐Nationwide Inpatient Sample (HCUP‐NIS) from 2002 through 2014. We obtained data from patients aged ≥18 years with diagnosis of “Alcoholic Cardiomyopathy.” Death was defined within the NIS as in‐hospital mortality. By using International Classification of Disease‐9th edition‐Clinical Modification (ICD‐9CM) diagnoses and diagnosis‐related groups different comorbidities were identified.Results: We studied a total of 45 365 admissions among patients with AC. The absolute number of admissions decreased from 2002 to 2014 (3866‐2834 admissions). In‐hospital mortality was variable throughout study duration without a clinically relevant trend (Mean 4.5%, range 3.6%‐5.6%). The patients were mostly male (87%) and Caucasian (50.5%). Commonest age groups involved were 45‐59 years (46.7%) followed by 60‐74 years (29.2%). Trends in associated comorbidities such as smoking, drug abuse, depression, and hypertension increased over the same time period. Among all admissions, almost half were for cardiovascular etiologies (48.9%) and heart failure (≈24%) was the commonest reason for hospital admission.Conclusion: While the overall admissions among patients with AC decreased over time, the proportion of patients with high‐risk characteristics such as smoking, depression, and drug abuse increased. Patients aged 45 and older were largely affected and cardiovascular etiologies predominated among causes for admission.
- Open Access
- 23 October 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (10) , 1298-1299
Reply: Surprisingly low incidence of left ventricular thrombosis in anterior ST‐segment elevation myocardial infarction
- 23 October 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (10) , 1298-1299
Open AccessReply: Surprisingly low incidence of left ventricular thrombosis in anterior ST‐segment elevation myocardial infarction
- Open Access
- 16 October 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (10) , 1289-1296
Left ventricular thrombosis in acute anterior myocardial infarction: Evaluation of hospital mortality, thromboembolism, and bleeding
Background: Left ventricular thrombosis (LVT) is a well‐known complication of acute myocardial infarction, most commonly seen in anterior wall ST‐segment elevation myocardial infarction (STEMI). It is associated with systemic thromboembolism.Hypothesis: Our aim was to evaluate the impact of LVT on in‐hospital mortality, thromboembolism, and bleeding in patients with anterior STEMI.Methods: Data was collected from the Nationwide Inpatient Sample where patients with a primary diagnosis of “Anterior STEMI” [ICD9‐CM code 410.1] were included. Comparisons were made between patients with LVT [ICD9‐CM code 429.79] vs those without using propensity score matching (PSM).Results: From 2002 to 2014, there were 157 891 cases of anterior STEMI. Among these, 649 (0.4%) had LVT. Post‐PSM, there was no difference in in‐hospital mortality between the groups with LVT and without (7.3% vs 8.6%). Thromboembolic event rate was higher with LVT compared to those without LVT (7.3% vs 2.1%). There was no difference in bleeding events between patients with LVT and those without (2.9% vs 3.2%). The baseline average length of stay in the group with LVT was longer than the group without LVT (7.9 ± 6.7 days vs 5.1 ± 6.0 days). The average hospitalization‐related costs were also significantly higher among patients with LVT compared to those without (95 598 USD vs 66 641 USD per stay) at baseline.Conclusion: Among patients hospitalized with anterior STEMI, presence of LVT is associated with increased thromboembolic events, average length of hospital stay and average cost of hospitalization. However, it is not associated with increased in‐hospital mortality or bleeding events.
- 16 October 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (10) , 1289-1296
Open AccessLeft ventricular thrombosis in acute anterior myocardial infarction: Evaluation of hospital mortality, thromboembolism, and bleeding
Background: Left ventricular thrombosis (LVT) is a well‐known complication of acute myocardial infarction, most commonly seen in anterior wall ST‐segment elevation myocardial infarction (STEMI). It is associated with systemic thromboembolism.Hypothesis: Our aim was to evaluate the impact of LVT on in‐hospital mortality, thromboembolism, and bleeding in patients with anterior STEMI.Methods: Data was collected from the Nationwide Inpatient Sample where patients with a primary diagnosis of “Anterior STEMI” [ICD9‐CM code 410.1] were included. Comparisons were made between patients with LVT [ICD9‐CM code 429.79] vs those without using propensity score matching (PSM).Results: From 2002 to 2014, there were 157 891 cases of anterior STEMI. Among these, 649 (0.4%) had LVT. Post‐PSM, there was no difference in in‐hospital mortality between the groups with LVT and without (7.3% vs 8.6%). Thromboembolic event rate was higher with LVT compared to those without LVT (7.3% vs 2.1%). There was no difference in bleeding events between patients with LVT and those without (2.9% vs 3.2%). The baseline average length of stay in the group with LVT was longer than the group without LVT (7.9 ± 6.7 days vs 5.1 ± 6.0 days). The average hospitalization‐related costs were also significantly higher among patients with LVT compared to those without (95 598 USD vs 66 641 USD per stay) at baseline.Conclusion: Among patients hospitalized with anterior STEMI, presence of LVT is associated with increased thromboembolic events, average length of hospital stay and average cost of hospitalization. However, it is not associated with increased in‐hospital mortality or bleeding events.
- 1 September 2018
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 19 (9) , 480-484
Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample
Background: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a limited number of studies. We therefore utilized a large national database to examine the prevalence of cardiovascular risk factors and events amongst patients with cannabis use. Methods: Patients aged 18–55 years with cannabis use were identified in the National Inpatient Sample 2009–2010 database using the Ninth Revision of International Classification of Disease code 304.3. Demographics, risk factors, and cardiovascular event rates were collected on these patients and compared with general population data. Results: Prevalence of heart failure, cerebrovascular accident (CVA), coronary artery disease, sudden cardiac death, and hypertension were significantly higher in patients with cannabis use. After multivariate regression adjusting for age, sex, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, tobacco use, and alcohol use, cannabis use remained an independent predictor of both heart failure (odds ratio = 1.1, 1.03–1.18, P < 0.01) and CVA (odds ratio = 1.24, 1.14–1.34, P < 0.001). Conclusion: Cannabis use independently predicted the risks of heart failure and CVA in individuals 18–55 years old. With continued legalization of cannabis, potential cardiovascular effects and their underlying mechanisms need to be further investigated.
- 1 September 2018
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 19 (9) , 480-484
Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample
Background: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a limited number of studies. We therefore utilized a large national database to examine the prevalence of cardiovascular risk factors and events amongst patients with cannabis use. Methods: Patients aged 18–55 years with cannabis use were identified in the National Inpatient Sample 2009–2010 database using the Ninth Revision of International Classification of Disease code 304.3. Demographics, risk factors, and cardiovascular event rates were collected on these patients and compared with general population data. Results: Prevalence of heart failure, cerebrovascular accident (CVA), coronary artery disease, sudden cardiac death, and hypertension were significantly higher in patients with cannabis use. After multivariate regression adjusting for age, sex, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, tobacco use, and alcohol use, cannabis use remained an independent predictor of both heart failure (odds ratio = 1.1, 1.03–1.18, P < 0.01) and CVA (odds ratio = 1.24, 1.14–1.34, P < 0.001). Conclusion: Cannabis use independently predicted the risks of heart failure and CVA in individuals 18–55 years old. With continued legalization of cannabis, potential cardiovascular effects and their underlying mechanisms need to be further investigated.
- Open Access
- 31 August 2018
- Published by Springer Nature in Cureus
- Vol. 10 (8) , e3243
Cardiovascular Autonomic Neuropathy and its Association with Cardiovascular and All-cause Mortality in Patients with End-stage Renal Disease
End-stage renal disease frequently leads to increased cardiovascular mortality. Cardiovascular autonomic neuropathy (CAN) may be predictive of cardiac arrhythmias and sudden cardiac death in patients with end-stage renal disease. A total of 70 patients with end-stage renal disease were included in the study. The assessment of cardiac dysautonomia was based on the four standardized tests performed at the baseline and, again, at the end of the study. The criteria for CAN included at least two abnormal test results. Fifty of 70 patients completed the study and were followed-up after one year. Out of the 50 patients, 44 (88%) had CAN at baseline. Twelve (24%) patients died at the one-year follow-up. Sudden cardiac death was reported in seven out of 12 (58%) patients. All seven patients who died had high dysautonomia scores (three abnormal tests) at the baseline. There was a significantly higher percentage of patients with all four abnormal tests amongst patients who died of any cause (56% vs. 17%; RR 6.07, 95% CI 1.29-28.49; p-value 0.02) or due to sudden cardiac death (43% vs. 10.5%; RR 6.37, 95% CI 1.03-39.36; p-value 0.04). All five patients who did not have CAN at the baseline developed this abnormality on repeat testing after one year. The prevalence of CAN in patients with end-stage renal disease on maintenance hemodialysis was significantly higher. CAN was an independent predictor of all-cause and cardiovascular mortality, which highlights it as a risk stratification tool in patients with end-stage renal disease.
- 31 August 2018
- Published by Springer Nature in Cureus
- Vol. 10 (8) , e3243
Open AccessCardiovascular Autonomic Neuropathy and its Association with Cardiovascular and All-cause Mortality in Patients with End-stage Renal Disease
End-stage renal disease frequently leads to increased cardiovascular mortality. Cardiovascular autonomic neuropathy (CAN) may be predictive of cardiac arrhythmias and sudden cardiac death in patients with end-stage renal disease. A total of 70 patients with end-stage renal disease were included in the study. The assessment of cardiac dysautonomia was based on the four standardized tests performed at the baseline and, again, at the end of the study. The criteria for CAN included at least two abnormal test results. Fifty of 70 patients completed the study and were followed-up after one year. Out of the 50 patients, 44 (88%) had CAN at baseline. Twelve (24%) patients died at the one-year follow-up. Sudden cardiac death was reported in seven out of 12 (58%) patients. All seven patients who died had high dysautonomia scores (three abnormal tests) at the baseline. There was a significantly higher percentage of patients with all four abnormal tests amongst patients who died of any cause (56% vs. 17%; RR 6.07, 95% CI 1.29-28.49; p-value 0.02) or due to sudden cardiac death (43% vs. 10.5%; RR 6.37, 95% CI 1.03-39.36; p-value 0.04). All five patients who did not have CAN at the baseline developed this abnormality on repeat testing after one year. The prevalence of CAN in patients with end-stage renal disease on maintenance hemodialysis was significantly higher. CAN was an independent predictor of all-cause and cardiovascular mortality, which highlights it as a risk stratification tool in patients with end-stage renal disease.